Secukinumab ELISA Kit (CosentyxÂ®/VerxantÂ®) Free drug
- Product type:
- Biosimilar ELISA
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit (HUMB00066)
The Assay Genie Secukinumab has been developed for the quantitative determination of Secukinumab in serum and plasma.
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Test Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for Secukinumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to Secukinumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The colour developed is proportional to the amount of Secukinumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Product Information
|Required Volume (µl)||10|
|Total Time (min)||70|
|Sample Typle||Serum, plasma|
|Number of Assays||96|
|Detection Limit (ng/mL)||6.25|
|Shelf Life (year)||1|
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit - General Information
Secukinumab is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, Secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Contents
|1x12x8||Microtiter Plate |
Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with reactant.
|0,3 mL (each)||Standards A-F (10x) |
Standard A: 1000 ng/mL
Standard B: 500 ng/mL
Standard C: 250 ng/mL
Standard D: 125 ng/mL
Standard E: 62.5 ng/mL
Standard F: 0 ng/mL
Used for the standard curve and control. Contains evolocumab, human serum and stabilizer, <0,1% NaN3.
Standards are prepared concentrated (10x).
|0,3 mL (each)||Controls |
Control low and high levels (10x)
Contains human serum and stabilizer, <0,1% NaN3.
Controls are prepared concentrated (10x).
|2x50 mL||Assay buffer |
Ready to use. Blue coloured. Contains proteins, <0,1% NaN3.
|1x12 mL||Horse radish peroxidase conjugated probe. |
Ready to use. Red coloured. Contains HRP conjugated probe, stabilizer and preservatives.
|1x12 mL||TMB substrate solution. |
Ready to use. Contains 3,3′,5,5′- Tetramethylbenzidine (TMB).
|1x12mL||TMB stop solution. |
Ready to use. 1N HCl
|1x50mL||Wash buffer (20x). |
Prepared concentrated (20x) and should be diluted with the dilution rate given in the “Pretest setup instructions” before the test. Contains buffer with tween 20.
|2x1||Adhesive Foil. |
For covering microtiter plate during incubation
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Protocol
|1||Pipette 100µl of Assay Buffer non-exceptionally into each of the wells to be used.|
|2||Pipette 20 µL of each diluted Standards, Low level control, High level control and samples into the respective wells of microtiter plate |
A1: Standard A
B1: Standard B
C1: Standard C
D1: Standard D
E1: Standard E
F1: Standard F
G1: Low level control
H1: High level control
A2 and on: Samples
|3||Cover the plate with adhesive foil. Briefly mix contents by gently shaking the plate. Incubate 30 minutes at room temperature (18-25°C)|
|4||Remove adhesive foil. Discard incubation solution. Wash plate three times each with 300 µL Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel|
|5||Pipette 100 µL Conjugate into each well|
|6||Cover the plate with adhesive foil. Incubate 30 minutes at room temperature (18-25°C)|
|7||Remove adhesive foil. Discard incubation solution. Wash plate three times each with 300 µL Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel|
|8||Pipette 100 µL Substrate into each well|
|9||Incubate 10 minutes without adhesive foil at room temperature (18-25°C) in the dark|
|10||Stop the substrate reaction by adding 100 µL Stop Solution into each well. Briefly mix contents by gently shaking the plate. Colour changes from blue to yellow.|
|11||Measure optical density with a photometer at OD 450nm with reference wavelength 650 nm (450/650 nm) within 30 minutes after pipetting the Stop Solution.|